Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.
Though the cancer vaccine field has seen more setbacks than successes, some companies are forging ahead with ambitious plans to push their therapeutics toward regulatory approval.
The therapeutic vaccines segment of the immunotherapy market is primed for growth, with a new report pegging their major-market sales at $1.2 billion in 2022. But vaccine makers will have their fair share of challenges navigating that market--not to mention the hurdles they'll have to clear to make it there in the first place.
Patients with a lethal form of brain cancer lived nearly twice as long as expected after receiving Agenus' ($AGEN) Prophage vaccine in a Phase II study, according to the company.
With the expected launch of Northwest Biotherapeutics' dendritic cell-based therapeutic vaccine DCVax-L, the glioblastoma multiforme drug market is expected to grow rapidly, from $305 million in 2012 to $583 million in 2019, according to market research.
Shares of Inovio Pharmaceuticals took a hit Tuesday on rumors that CEO Joseph Kim was "walking back expectations" for a Phase II study of DNA vaccine candidate VGX-3100 in women with cervical precancerous lesions.
Things haven't been pretty for Dendreon since its highly anticipated cancer vaccine Provenge stumbled out of the gate. Now that disappointing sales, increased competition and cost-control struggles have taken their toll, the Seattle-based company is up against a mountain of debt. But CEO John Johnson won't be around to help right the company's course.
Back in April, Amgen's cancer-fighting viral vaccine stumbled in Phase III, missing on overall survival, a secondary endpoint. But that won't stop the California company from seeking regulatory approval, it announced early this week.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.